Crinetics Pharmaceuticals Stock Price, News & Analysis

Crinetics (Nasdaq: CRNX) announced dosing of the first patient in the CALM-CAH Phase 3 trial of atumelnant on December 11, 2025. The randomized, placebo-controlled adult study will evaluate atumelnant’s ability to reduce excess adrenal androgens and lower glucocorticoid use while assessing other clinical outcomes that reflect disease control.

Atumelnant is described as the first-and-only small-molecule ACTH receptor antagonist in late-stage clinical development for classic congenital adrenal hyperplasia (CAH). Phase 2 data showed rapid, sustained reductions in biomarkers including androstenedione and 17-hydroxyprogesterone, plus clinical measures such as adrenal size and resumption of menses. Atumelnant has also received FDA Orphan Drug designation for classic CAH.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on December 10, 2025 inducement equity awards under its 2021 Inducement Plan to nine new non-executive employees.

The Compensation Committee granted an aggregate of 39,575 non-qualified stock options and 26,525 restricted stock units (RSUs). Options have an exercise price of $48.06, equal to the Dec. 10, 2025 closing price. Options vest over four years (25% at one year, then monthly over 36 months); RSUs vest in four equal annual installments, all subject to continued employment and plan terms. Grants were made pursuant to Nasdaq Listing Rule 5635(c)(4).

Crinetics (Nasdaq: CRNX) announced the first patient has been dosed in the Phase 1/2 BRAVESST2 trial evaluating CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors and other SST2-expressing tumors on Dec 3, 2025.

CRN09682 is the lead candidate from Crinetics’ proprietary nonpeptide drug conjugate (NDC) platform, designed for selective SST2 binding, rapid receptor internalization, and intratumoral release of a cytotoxic payload. The first-in-human, open-label study will assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity across dose-escalation and dose-expansion phases, enrolling up to 150 participants with SST2 confirmation by somatostatin receptor imaging.

Crinetics (Nasdaq: CRNX) announced the first patient randomized in the pivotal Phase 3 CAREFNDR trial of once-daily oral paltusotine for adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors on Nov 20, 2025.

The randomized, double-blind, placebo-controlled study will enroll 141 adults randomized 2:1 to paltusotine 80 mg or placebo; the primary endpoint is change in flushing episodes/day from baseline to Week 12 and a key secondary is change in bowel movements/day. The trial includes a 16-week randomized period followed by a 104-week open-label extension that will evaluate long-term efficacy, safety and monitor progression-free survival. Global enrollment is expected through 2025–2026.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that on November 10, 2025 its Compensation Committee granted inducement equity awards to 11 new non-executive employees under the 2021 Inducement Plan.

The awards consist of 37,675 non-qualified stock options and 25,300 restricted stock units (RSUs). The options have an exercise price of $41.45, equal to the closing Nasdaq price on November 10, 2025. Options vest over four years (25% at year one, then 36 monthly installments); RSUs vest in four equal annual installments, both subject to continued employment and award agreement terms. Grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals (Nasdaq: CRNX) reported Q3 2025 results and a business update following the U.S. FDA approval and U.S. launch of PALSONIFY (paltusotine) on September 25, 2025. Early launch indicators show field coverage to >95% of priority HCPs, ~95% of filled prescriptions from switch patients, and ~50% of filled prescriptions reimbursed.

Q3 financials: revenue $0.1M, R&D $90.5M, SG&A $52.3M, net loss $130.1M. Cash and investments $1.1B as of Sept 30, 2025, with projected cash runway into 2029 and 2025 cash use guidance of $340–370M. Multiple clinical milestones expected Q4 2025–H1 2026; some IND timing shifted for SST3 and TSHR programs.

Crinetics (Nasdaq: CRNX) will present three abstracts at the North American Neuroendocrine Tumor Society Annual Meeting (NANETS 2025), October 23-25, 2025, in Austin, Texas.

Key highlights include a preliminary, investigator-assessed one-year progression-free survival (PFS) rate of 74% from an open-label Phase 2 study of paltusotine for carcinoid syndrome and poster details on the randomized Phase 3 CAREFNDR study of paltusotine and the first-in-human study of nonpeptide drug conjugate CRN09682. Paltusotine is marketed in the U.S. as PALSONIFY for acromegaly but is not approved for carcinoid syndrome.

Crinetics Pharmaceuticals (NASDAQ: CRNX) announced on October 10, 2025 inducement equity awards under its 2021 Inducement Plan for 20 new non-executive employees.

The Compensation Committee granted 78,975 non-qualified stock options (exercise price $44.93, equal to the Oct 10, 2025 closing price) and 54,475 restricted stock units (RSUs). Options vest over four years (25% at one year then 36 monthly instalments); RSUs vest in four equal annual instalments, each subject to continued employment. Awards were made pursuant to Nasdaq Listing Rule 5635(c)(4) and are governed by the 2021 Inducement Plan and award agreements.

Crinetics Pharmaceuticals (Nasdaq: CRNX) will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.

Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update. Dial-in numbers are provided for domestic and international callers and the access code 166837 applies. A live webcast will be available via the company's Events/Investor Relations pages and will be archived for later viewing. Participants are recommended to connect at least 15 minutes before the scheduled start to ensure a timely connection.